Related Articles

In the literature…

Proven Efficacy with Combination Therapy

For patients taking AChEIs

Improve memory and language

Improves and maintains cognition above baseline⁹

Results from a randomized, multicenter, double-blind, parallel-group, placebo-controlled US study investigating the efficacy of NAMENDA plus donepezil in patients with moderate to severe AD. Results shown are from OC analysis. The study involved 404 outpatients ≥50 years of age with an MMSE score of ≥5 to ≤14 points. Patients were randomized to treatment with NAMENDA (10 mg BID) or placebo added to a stable regimen of donepezil† (5 mg-10 mg/day) for 24 weeks. At week 24, 322 patients (172 NAMENDA, 150 placebo) completed the study.⁹

• NAMENDA in combination with donepezil significantly improved and sustained cognitive performance above baseline for 6 months vs progressive decline seen with donepezil and placebo (P<0.001)^†9
• NAMENDA+donepezil provided significant benefits in:¹⁰
  • Memory (P=0.042)
  • Language (P=0.006)
  • Praxis [performing familiar actions] (P=0.002)

Significant benefits in functional communication and language^4,9,11

Post hoc results from a randomized, multicenter, double-blind, placebo-controlled US study investigating the efficacy of NAMENDA plus donepezil in patients with moderate to severe AD. Results shown are from OC analysis. Language items from the SIB were consolidated into 3 subscales based on linguistic parameters. Items assessing functional communication from the ADCS-ADL₁₉ and BGP were consolidated into one functional communication score. The study involved 404 outpatients >50 years of age with an MMSE score of ≥5 to ≤14 points. Patients were randomized to treatment with NAMENDA (10 mg BID) or placebo added to a stable regimen of donepezil (5 mg-10 mg/day) for 24 weeks. At week 24, 322 patients (172 NAMENDA, 150 placebo) completed the study.^4,9

• Patients taking NAMENDA+donepezil performed significantly better on naming tasks versus patients taking placebo+donepezil at week 24 ( P<0.01)⁴
• Caregivers reported significantly better functional communication abilities in patients taking NAMENDA+donepezil vs patients taking placebo+donepezil at week 24 ( P<0.01)⁴

Enhancing patients' abilities to communicate socially and interact with others may increase connectedness with family members

^§ADCS-ADL =Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory. A comprehensive battery of 19 ADL items aimed at measuring the functional ability of patients with moderate to severe AD. ADCS-ADL¹⁴ item responses range from total independence to total disability.¹⁵

^||BGP=Behavioral Rating Scale for Geriatric Patients. A 35-item, observer-rated scale for the assessment of functional and behavioral disturbances of geriatric patients. The care dependence subscale includes 23 items^13,16

Proven efficacy in day-to-day function

Significant functional benefits in combination⁹

Results from a randomized, multicenter, double-blind, parallel-group, placebo-controlled US study investigating the efficacy of NAMENDA plus donepezil in patients with moderate to severe AD. Results shown are from OC analysis. The study involved 404 outpatients ≥50 years of age with an MMSE score of ≥5 to ≤14 points. Patients were randomized to treatment with NAMENDA (10 mg BID) or placebo added to a stable regimen of donepezil (5 mg-10 mg/day) for 24 weeks. At week 24, 322 patients (172 NAMENDA, 150 placebo) completed the study.⁹

• NAMENDA+donepezil showed significantly less decline in daily activities vs donepezil+placebo, even after 6 months (P=0.02)⁹

Efficacy in key activities of daily living^4,17

Results from a randomized, multicenter, double-blind, parallel-group, placebo-controlled US study investigating the efficacy of NAMENDA plus donepezil in patients with moderate to severe AD. Results shown are from OC analysis. ADLs were consolidated into 4 subscales based on a factor analysis. The study involved 404 outpatients ≥50 years of age with an MMSE score of ≥5 to ≤14 points. Patients were randomized to treatment with NAMENDA (10 mg BID) or placebo added to a stable regimen of donepezil (5 mg-10 mg/day) for 24 weeks. At week 24, 322 patients (172 NAMENDA, 150 placebo) completed the study.^4,9,17

• NAMENDA-treated patients maintained significantly more connectedness, autonomy and higher-level functioning than patients taking donepezil + placebo (P<0.05)¹⁷

Improve and delay behavioral symptoms

Delaying symptoms of agitation, irritability, and nighttime behavior can help make life more manageable for patients and their families

Improve symptoms

Significantly improves behavior^9,18

Results of a randomized, multicenter, double-blind, parallel-group, placebo-controlled US study investigating the efficacy of NAMENDA in 404 patients with moderate to severe AD. Results shown are from OC analysis. Patients were ≥50 years of age with an MMSE score of ≥5 to ≤14 points. Patients were randomized to treatment with NAMENDA (10 mg BID) or placebo added to a stable regimen of donepezil (5 mg-10 mg/day) for 24 weeks. At week 24, 322 patients (172 NAMENDA, 150 placebo) completed the study.^9,18

Caregivers report benefits in behavior^4,9,18

• NAMENDA+donepezil significantly improved and maintained behavior above baseline for 6 months compared with the progressive decline seen with patients taking donepezil+placebo (P=0.01)⁹
• NAMENDA+donepezil provided significant reductions in behavioral symptoms⁴:
  • Agitation/aggression (P=0.001)
  • Irritability/lability (P=0.003)

Delay onset of symptoms

Delays onset of behavioral symptoms in asymptomatic patients^9,18

Results of a randomized, multicenter, double-blind, parallel-group, placebo-controlled US study investigating the efficacy of NAMENDA in 404 patients with moderate to severe AD. Results shown are from last observation carried forward (LOCF) analysis. Patients were ≥50 years of age with an MMSE score of ≥5 to ≤14 points. Patients were randomized to treatment with NAMENDA (10 mg BID) or placebo added to a stable regimen of donepezil (5 mg-10 mg/day) for 24 weeks. At week 24, 322 patients (172 NAMENDA, 150 placebo) completed the study.^9,18

• Significantly more patients remained asymptomatic with NAMENDA+donepezil vs donepezil+placebo for the following behavioral measures¹⁸:
  • Agitation/aggression (P=0.016)
  • Irritability/lability (P=0.041)
  • Nighttime behavior (P=0.027)